Zika Virus Infection
Conditions
Keywords
trophoblast, placenta
Brief summary
Prospective, non-interventional study carried out after culturing placental trophoblastic tissue ex vivo and infection with Zika and Tonate
Detailed description
The analysis will relate for each virus studied + control + favipiravir to 1 placenta in the 1st trimester and 1 placenta at term. 2 experiments per virus will be planned.
Interventions
C6/36 cells will be cultured in L15 culture medium (Leibovitz's L-15 medium), supplemented with 5% FBS (Fetal Bovine Serum) and 1% penicillin/streptomycin at 28°C in a humidified atmosphere containing 5% C02. ZIKV and TONV will be expanded and titrated using C6/36 cells. The viral stock will be aliquoted in 100 µL aliquots and stored at -80°C.
Placental tissues will be handled within one hour of delivery. The chorionic villi will be dissected into 5mm sections and the tissues washed abundantly, minimum 3 times with a standard culture medium (RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 1% L-Glutamine and 1% Penicillin/Streptomycin) to remove maternal blood, membranes and blood clots. Collagen gel sponges will be placed in 6-well plate wells containing 3mL of culture medium (RPMI-1640 supplemented with 15% heat-inactivated fetal bovine serum (FCS), 1% Penicillin/streptomycin, 0 1% Gentamycin, 1% Amphotericin B, 1% L-Glutamine, 1% non-essential amino acid, 1% sodium pyruvate) per well. Chorionic villi will be dissected into 5mm sections and placed on top of collagen gel sponges at the interface between culture medium and air.
The tissues will be lysed by mechanical disruption in a lysis buffer + 4%TCEP (Tris(2-carboxyethyl)phosphine hydrochloride) (Machery-Nagel ref: 740395.107) with the Precellys system. The lysed tissues will be diluted in 100 mg/mL of Macherey-Nagel lysis buffer, aliquoted and stored at -80°C until extraction. Total RNA will be extracted in duplicate using the Nucleospin 96 RNA Core kit (Macherey Nagel ref: 740466.4), following the supplier's instructions. Standard samples, controls and ZIKV and TONV viral RNA will be extracted and tested in parallel under the same conditions. The extracted RNA will be subjected to reverse transcriptase, using the Superscript One-Step RT-qPCR kit (Invitrogen ref: 11732088) according to the manufacturer's recommendations, with a probe and primer specific for ZIKV and TONV.
Sponsors
Study design
Eligibility
Inclusion criteria
* Patient over 18 years old * Singleton pregnancy of normal course, at term, birth by caesarean section OR * Trophoblast from Voluntary Termination of Pregnancy (IVG), after endo-uterine aspiration
Exclusion criteria
* Need for pathological, genetic or bacteriological examination of the placenta * Multiple pregnancy * HBV+ (Hepatitis B positive), HCV+ (Hepatitis C positive) , known CMV seroconversion during pregnancy (CytoMégaloVirus) * Immunosuppression (drugs, corticosteroids, etc.) * Diabetes * Pre eclampsia * Intrauterine growth retardation (IUGR), * Vascular or placental pathology. * Refusal to participate * Patient under guardianship / curatorship / security measure * Patient under AME (state medical aid)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To assess the replication potential of TONV and ZIKV after placenta infection ex vivo. | inclusion | Determine the viral load (RT-qtPCR) of TONV and ZIKV after placenta infection, ex vivo in RNA copies/mL |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Validate the ex vivo placental model for TONV. | Inclusion | Analysis of viral load in placental explants for TONV in RNA copies/mL |
| Compare viral infection of the placenta at different terms of pregnancy (first trimester and term). | first trimester | Analysis of the viral load according to the term in RNA copies/mL |
| Compare the placental infection of TONV versus ZIKV. | inclusion | Analysis of viral load depending on the virus (ZIKV vs TONV) in RNA copies/mL |
| Highlight the cellular targets of TONV. | inclusion | Histological analysis and labeling of TONV cells in RNA copies/mL |